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Immune thrombocytopenia is an autoimmune disease with abnormal biomarkers. Immune thrombocytopenia
pathogenesis is a complicated process in which the patient’s immune system is activated by platelet autoantigens
resulting in immune mediated platelet destruction or suppression of platelet production. The autoantibodies
produced by autoreactive B cells against self antigens are considered to play a crucial role. In addition, biomarkers
such as transforming growth factor-beta1,Toll-like receptors,T helper 1 andT helper 2 cytokine bias, Notch signaling
and abnormal biomarker in megakaryocyte maturation are involved in the pathogenesis of this disease. With the
genomewide association study on immune thrombocytopenia, more biomarkers will be founded in the future. They
may provides a theoretical basis for the mechanism and treatment of immune thrombocytopenia.
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Immune thrombocytopenia (ITP) is an autoimmune
bleeding disorder in which the patient’s immune system is
activated by platelet autoantigens resulting in immune-
mediated platelet destruction and/or suppression of plate-
let production with the clinical manifestations of oral
gingival and skin mucous membrane bleeding.
Biomarkers are very important to the pathogenesis of
disease. Many abnormal immune biomarkers play crucial
roles in ITP pathogenesis [1]. The abnormal B, T cell
and some new biomarkers in ITP were introduced. It
may help people to know the complicated pathogenesis
of ITP.Abnormal B cell immune biomarkers
ITP is an autoimmune disease. Glycoprotein (GP) spe-
cific autoantibodies (e.g., GPVI, GPIb/IX, GPIIb/IIIa
autoantibodies) can be detected in most ITP patients’
plasma or platelet eluates by modified monoclonal
antibody immobilization of platelet antigen (MAIPA)
assay, which bind to the specific glycoproteins by an
antigen-binding fragment (Fab) and then activate the
mononuclear-macrophage or complement system [2, 3].
The autoantibodies produced by autoreactive B cells
against self-antigens, specifically immunoglobulin G (IgG)Correspondence: jmm7751@163.com
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ered to play a crucial role in the plaletet destruction [4].
Approximately 75 % of platelet autoantigens are local-
ized to either the platelet GP IIb/IIIa or GP Ib/IX com-
plex. Inhibition of the binding of autoantibodies from
several ITP patients by either another ITP autoantibody
or by a monoclonal anti-GPIIb/IIIa antibody suggests
that the antigenic repertoire in chronic ITP may be lim-
ited. Many patients may produce multiple antibodies.
Once produced, antiplate autoantibodies may either bind
to platelets, causing their destruction by either phagocyt-
osis or possibly complement activation and lysis, or bind
to megakaryocytes, resulting in decreased thrombopoi-
esis. A variety of new investigative techniques including
MAIPA assay have localized a few autoantigens to spe-
cific regions of the cytoplasmic or extracellular regions
of both GPIIb/IIIa and GPIb/IX. These methods that
allow incubation of patient serum or plasma with intact
platelets (MAIPA and immunobead) have greater sensitiv-
ity than techniques in which the patient antibody is tested
against previously isolated platelet glycoproteins [5].
Platelets with affiliated IgG are targeted for exploitation
by Fc receptor-mediated phagocytic cellular material
within the reticuloendothelial system. The expression of
FC gamma receptors (FCGR) IIb was decreased in ITP.
Lower expression of FCGRIIb may be involved in the
pathogenesis of ITP. An increasing in FCGRIIb may be
considered as a therapeutic target for human ITP treat-
ment or possibly as a new biomarker for ITP analysis [6].distributed under the terms of the Creative Commons Attribution License
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and elevated expression of FCGRIIa and FCGRIII on
monocytes in ITP patients before high-dose dexametha-
sone (HDDXM) therapy. HD-DXM treatment may change
the FCGR balance toward the inhibitory FCGRIIb, thus
providing new insights into the mechanism of HD-DXM
in the treatment of ITP [7].
B-cell activating factor (BAFF; also known as B-
lymphocyte stimulator) belonging to the family of tumor
necrosis factor (TNF) ligands is critical for the mainten-
ance of normal B-cell development, homeostasis, and
autoreactivity [8, 9] and T-cell costimulation [10–12].
BAFF is an important homeostatic cytokine for B cells
that is up-regulated during inflammation and links adap-
tive with innate immunity. BAFF has been shown to
enhance the expression of CD19 and mediate the matur-
ation of autoreactive B cells. It is shown that BAFF is ele-
vated in ITP patients with active disease, and excessive
BAFF may rescue autoreactive B and T cells from apop-
tosis [13].
Abnormal T cell immune biomarkers
The cytokine transforming growth factor-beta1 (TGF-β1)
is a central player in maintaining the immune response
balance, which belongs to regulator T cell (Treg) cyto-
kines. Tregs play crucial roles in the induction and main-
tenance of immune tolerance, which are involved in ITP
abnormal T cell immunity. It was found that the concen-
tration TGF-β1 was lower in ITP patients [14]. The dom-
inant function of TGF-β1 is to regulate peripheral
immune homeostasis [15].
Toll-like receptors (TLRs) are the major molecules in-
volved in the immune regulatory process [16, 17]. TLRs
play an important role in defending the host against
pathogenic microbes through the induction of inflamma-
tory cytokines and type I interferons. Furthermore, TLRs
play roles in shaping pathogen-specific humoral and cellu-
lar adaptive immune responses [18]. TLRs have been
found to be associated with immune-mediated diseases
but it is still not clear whether they play a role in ITP, es-
pecially TLR4. CD4+ T-lymphocyte abnormalities, includ-
ing T helper (Th)17. Th1, Th2, and Treg are considered
important in ITP. It was showed that TLR4, CD4+ T cells
(Th1, Th17 and Treg cells) and related cytokines may take
part in the pathogenesis of ITP. TLR4 may play a role
through the TLR4-cytokine-CD4+ T lymphocyte cell
pathway [19].
Th1 polarization persists in the autoimmune response
found in ITP. TLR7 expression, which also plays an im-
portant role in autoimmune diseases, was found increas-
ing in ITP. The findings indicate that TLR7 promotes Th1
polarization and may contribute in ITP pathogenesis [20].
Th1/Th2 cytokine bias may be an important mechan-
ism of ITP. The Th1/Th2 balance is important to normalhuman immunity. Th1 cells primarily secrete the inflam-
matory cytokines interleukin (IL)-2, IL-12, interferon-
gamma (IFN-γ) and TNF-β. Th2 cells primarily secrete
the inflammatory cytokines IL-4, IL-5, IL-6 and IL-10.
ITP is associated with a Th1 type of T helper cytokine
response, while that of type Th2 is downregulated. The
present study demonstrates that an imbalance of Th1
and Treg cytokines may mediate the pathogenesis of ITP
[21]. Uncontrolled Th-1 lymphocyte activation may be
an important mechanism of ITP. Treatment with a large
dose of dexamethasone, the Th1-type cytokine spectrum
returns to the dominant position after treatment with
dexamethasone [22]. Shifting the cytokine patterns from
Th1 to Th2 may be a potential immunotherapy for ITP.
Cytotoxic T-lymphocytes (CTLs) can induce the lysis of
autologous platelets. CTLs-mediated platelet destruction
and aberrant cytokine profiles play important roles in the
pathogenesis of ITP. Interleukin-27 (IL-27) has pleiotropic
immunomodulatory effects. The results suggest that IL-27
can inhibit CTL-mediated platelet destruction by negatively
regulating CTL cytotoxicity toward platelets in ITP. IL-27
may have a therapeutic role in treating ITP patients [23].
Notch signaling has been implicated in peripheral T-
cell activation and effector cell differentiation. Th17 cells
and Treg cells, along with Th1 and Th2 cells, may con-
tribute to the pathogenesis of ITP. The imbalance of
Th17/Treg toward Th17 cells has been shown to play an
important role in the peripheral immune response.
However, the role of Th17/Treg in the pathogenesis of
ITP and the effect of Notch signaling on Th17/Treg im-
balances still remain uncertain in ITP [24].
To investigate the role of Notch signaling pathway in
ITP, the expression of Notch pathway molecules in ITP
patients were measured and evaluated their clinical
relevance. It was found that Notch1 and Notch3 ex-
pression elevated, while Notch2 decreased statistically
in ITP patients. The findings suggest that the Notch
signaling pathway may be involved in ITP. The block-
age of Notch1 pathway may be a promising therapeutic
method [25].
Abnormal biomarker in ITP megakaryocyte maturation
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) belongs to the TNF super-family protein bio-
markers. TRAIL can promote the apoptosis and matur-
ation of megakaryocytes. It was demonstrated that low
expression of TRAIL in megakaryocytes contributed to
impaired platelet production in ITP. TRAIL expression
on megakaryocytes and the TRAIL concentrations of
ITP patients were decreased. Megakaryocyte apoptosis
mediated by TRAIL in the plasma of ITP patients may
be a potential mechanism by which the megakaryocyte
number increases in vitro [26]. It was found that low
dose decitabine can promote megakaryocyte maturation
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in megakaryocytes in healthy controls and ITP [27].
New biomarkers in ITP
Genetic sequence variations, such as single nucleotide
polymorphisms (SNPs), may have biological roles in modi-
fying the outcome risk of many diseases. Genomewide as-
sociation study(GWAS) is a new method that can be used
to find genetic characteristic SNPs of many complex dis-
ease by case–control association analysis [28, 29]. GWAS
on ITP may find some genetic SNPs which can be devel-
oped to new biomarkers for the clinical practice, individu-
alized diagnosis and treatment of ITP.
Conclusions
ITP is an autoimmune disease with abnormal immune
biomarkers. The autoantibodies produced by autoreactive
B cells against self-antigens, specifically antibodies against
GPIIb/IIIa and/or GPIb/IX, are considered to play a cru-
cial role in the pathogenesis of ITP. Biomarkers such as
TGF-β1,TLRs, Notch signaling, TRAIL,Th1/Th2 cytokine
bias are involved in ITP T cell abnormality. With the
GWAS on ITP, more biomarkers will be founded in the
future. They may provides a theoretical basis for the
mechanism and treatment of ITP.
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